pd 173074 has been researched along with Adenocarcinoma, Endometrioid in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Human endometrial cancer cell lines with wild-type or activating FGFR2 mutations were used to determine any synergism with concurrent use of the pan-FGFR inhibitor, PD173074, and the chemotherapeutics, doxorubicin and paclitaxel, on cell proliferation and apoptosis." | 1.38 | Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells. ( Byron, SA; Loch, DC; Pollock, PM, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byron, SA | 1 |
| Loch, DC | 1 |
| Pollock, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)[NCT02558348] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to Sponsor termination) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for pd 173074 and Adenocarcinoma, Endometrioid
| Article | Year |
|---|---|
Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Endometrioid; Cell Proliferation; Dose-Response Relationship, Drug | 2012 |